Engitix has appointed Sonia Quaratino in the newly created role of Executive Vice President (EVP) Chief Medical Officer (CMO). Quaratino has served as an independent non-executive Director on Engitix’s board since 2023 and will take responsibility for all aspects of the company’s clinical and medical strategy.
With more than 35 years of experience spanning immunology and oncology research, clinical development, and strategic leadership across biotechnology, pharmaceutical companies, and academia, Quaratino brings deep expertise in chronic inflammatory diseases, autoimmunity, and oncology.
Giuseppe Mazza, Co‑Founder and CEO of Engitix, said: “Sonia brings a rare combination of scientific depth and proven corporate leadership. Her extensive experience in immunology, clinical development and translational science, combined with the strategic insights she has already delivered during her tenure on our Board, will be invaluable.”
Quaratino most recently served as EVP CMO at Innate Pharma, and prior to that CMO of Georgiamune and Kymab. She held senior positions in pharma at Novartis and Merck KGaA following an academic career as Professor of Immunology at the University of Southampton. In addition to her role as CMO at Engitix, Dr Quaratino is a Member of the Board of Advisors at Pureos Bioventures.
Quaratino said: “Engitix’s proprietary human ECM drug discovery platform holds immense power; by enabling the study of disease biology directly within human tissues, it has successfully uncovered novel drug targets critical to treat fibrosis, solid tumours and inflammation. With a highly promising pipeline of preclinical first-in-class assets already in place, I look forward to designing and executing the clinical strategies that will progress these potentially life-changing therapies into human trials and address profound unmet needs for patients.”